Mock FDA Inspection
An FDA Consulting FirmWe specialize in Mock FDA Inspection and Remote Regulatory Assessments (RRA) for medical device and pharmaceutical manufacturers worldwide. Whether you are preparing for an on-site audit under CP 7356.002 or a remote QMSR (CP 7382.850) evaluation, our former FDA investigators provide high-fidelity simulations to ensure your team is ready. We offer both on-site global travel and virtual ‘Digital War Room’ coaching, but our 2026 schedules are filling up fast.
About Our FDA Consultant
Knowledge & Experience
Don’t Settle For Less
Mock FDA Inspection by
Former FDA Investigator
A second look by an ex-FDA investigator can save you a lot of trouble in the long run. We understand both sides of the process because we have been in the FDA as well as in the industry. In that sense, we can wear both the “white hat” and “black hat” at the same time during a mock FDA inspection. This dual perspective allows AP FDA Consulting to conduct audits that “feed two birds with one seed”—ensuring regulatory compliance while optimizing industrial efficiency.
Specialized Regulatory Expertise:
-
- QMSR & ISO 13485: We lead organizations through the critical transition from 21 CFR 820 to the new Quality Management System Regulation (QMSR), ensuring seamless alignment with ISO 13485:2016. CP 7382.850: Our audits are built on the foundation of the FDA’s own inspectional program for medical devices, simulating the exact rigor of a federal investigator.
- MDSAP (Medical Device Single Audit Program): We conduct preparation audits that align your system with the requirements of the US, Canada, Brazil, Japan, and Australia, allowing one audit to satisfy multiple jurisdictions.
- 21 CFR Part 4 (Combination Products): We provide specialized oversight for products at the intersection of drugs and devices, managing the complex co-packaging and cross-labeled requirements of Part 4.
- Pharmaceutical CGMP Compliance Program 7356.002: Specialized auditing for 21 CFR Part 210 (Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs), Part 211 (Finished Pharmaceuticals), 21 CFR Part 212 (PET).
Combination Products
We are former medical device and drug investigators with experience in 21 CFR 211 (cGMP) and 21 CFR 820 (QMSR).
Medical Device Manufacturers
Our ex-FDA investigator can assist you with preparing for your upcoming FDA inspection: QMSR and ISO 13485.
Pharmaceutical Manufacturers
Form FDA-483 Response
Work with a former FDA Investigator who issued numerous FDA Form 483 inspectional observations. Learn what drives regulatory escalation, and what typically triggers a Warning Letter.
Remote Regulatory Assessment (RRA)
Have a former FDA Investigator conduct your mock remote FDA inspection. Practice in real time and learn how to host FDA investigators remotely with structure, control, and confidence.
Warning Letter Response
Let a former FDA Compliance Officer who issued numerous Warning Letters assist you in preparing a precise and defensible Warning Letter response.
The Insider’s Playbook
Master Your Mock FDA Inspection
If you’re a manufacturer of medical devices or drugs, you cannot afford to take a chance with the FDA. There is no such thing as being over-prepared for an inspection; the agency’s investigators are responsible for protecting American consumers and will stop at nothing until they are satisfied you are compliant with the Federal Food, Drug, and Cosmetic Act.
With over 30 years of experience, we provide an “inside-out” perspective that bridges the gap between the Federal Food, Drug, and Cosmetic Act and your daily operations. We understand the high stakes: a single Warning Letter can cost millions of dollars and countless labor hours to remediate. Our mock FDA inspection identifies critical gaps before the FDA does, ensuring your facility remains in a state of continuous operational readiness.
The Danger of “Consultant Theory” vs. “Investigator Reality”
Too often, manufacturers make the fatal mistake of hiring consultants for mock FDA inspections who lack actual agency experience. It is crucial to hire specialists with a deep understanding of FDA laws. We provide the experience of a principal auditor who served as an ex-FDA Investigator, Compliance Officer, and Supervisor Investigator. We have sat on the other side of the table for years and know exactly what inspectors are thinking and planning.
2026 Shift: The Remote Regulatory Assessment (RRA)
The FDA is rapidly escalating the use of Remote Regulatory Assessments (RRA) as a primary enforcement tool. In 2026, these are no longer optional “desk reviews”; they are high-pressure, mandatory data inspections.
- The Digital Risk: If your facility is not “Digital War Room” ready, you risk an immediate Warning Letter or Import Alert without an investigator ever stepping through your door.
- Beyond Connectivity: An RRA readiness plan requires more than a stable internet connection; it requires a team that can defend a CAPAvia webcam.
- Digital Red Flags: Most firms fail RRAs because of digital delivery. We test your 24-hour upload speed and your SME’s webcam etiquette to ensure your 704(a)(4) request response is flawless.
The Technical “Six-System” Inspection Model (CP 7356.002)
To succeed in a mock FDA cGMP inspection, you must mirror the exact methodology used by FDA investigators. Under Compliance Program 7356.002, the FDA audits through a systematic “Six-System” model.
- Quality System: The “Sun” of your compliance. It is mandatory for every inspection and focuses on CAPA, change control, and management responsibility.
- Facilities and Equipment: Focuses on cleaning validation, HVAC, and calibration.
- Materials System: Covers supplier qualification, identity testing, and storage.
- Production System: Reviews batch records and process validation (PPQ).
- Packaging and Labeling: Focuses on line clearance and label reconciliation.
- Laboratory Control: Scrutinizes stability testing, method validation, and OOS (Out of Specification)investigations.
QMSR and Combination Products
As of February 2, 2026, the biggest shift for combination products is the mandatory alignment with the Quality Management System Regulation (QMSR).
- ISO 13485 Alignment: Drug-led facilities must now comply with “Device” clauses mapped to ISO 13485:2016.
- Risk Management: Under ISO 14971, a Risk Management File (RMF) must span the entire product lifecycle.
- Management Scrutiny: The FDA can now inspect management review minutes for the device constituent—records previously considered “off-limits”.
The Economics of Prevention
The fate of your organization can depend on these inspections. Correcting a Form 483 is far more expensive than a proactive mock FDA audit.
- Risk Management: Routine mock inspections are not optional; they are a necessary form of risk management.
- The Domino Effect: Once a quality system goes out of control, it is nearly impossible to fix inexpensively.
- Data Integrity (ALCOA+): 2026 inspections prioritize the automated review of electronic audit trails (CDS/LIMS).
Schedule Your Expert Mock Audit Today
A prior “NAI” classification does not guarantee a pre-announced inspection. Our mock FDA inspection setting is as realistic as possible, typically spanning 4-5 days of rigorous facility tours and record reviews. Don’t settle for second best. Qualifications and experience are the critical factors for your success. Contact us today to ensure your team is technically and psychologically prepared for the FDA.
Time is of the essence. We have a few remaining slots this year—schedule your Mock FDA Inspection today to ensure your team is confident and prepared.
This is a mock FDA inspection and not a comprehensive audit. However, by law, you will be required to perform an annual comprehensive internal audit. In fact, we can do it for you, but we will have to spread it throughout the year.
Why Choose an ex-FDA Investigator?
Hiring consultants without direct agency experience is a common, and often fatal, mistake. Our principal auditors have supervised medical device and drug investigators and understand exactly what inspectors are thinking and planning.
- Unbiased Insight: We provide a “different set of eyes” to detect overlooked gaps in your quality system.
- Economical Solutions: Correcting observations on a Form 483 is far more expensive than a proactive mock inspection.
- Global Expertise: Our team travels globally to support manufacturers, often combining projects to save clients up to 50% on travel expenses.
- Tactical Rehearsal: Just as athletes strategize to win, manufacturers must rehearse to ensure peak performance during a high-stakes audit.
IMPORTANT UPDATE: FOREIGN MANUFACTURERS
As of May 2025, the U.S. Food and Drug Administration (FDA) has formally expanded its enforcement policy to include unannounced inspections of overseas manufacturers. This marks a significant shift. The FDA has confirmed that advance notice will not be provided. ISO 13485 certification alone does not equate to inspection readiness. Foreign medical device and drug manufacturers must now operate with the same level of preparedness as U.S. establishments.